Viridian Therapeutics Files 8-K on Financials
Ticker: VRDN · Form: 8-K · Filed: Nov 12, 2024 · CIK: 1590750
Sentiment: neutral
Topics: financial-reporting, corporate-actions
Related Tickers: VRDN
TL;DR
Viridian Therapeutics (VRDN) filed an 8-K detailing financial results and operations.
AI Summary
Viridian Therapeutics, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. The company was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
Why It Matters
This 8-K filing provides an update on Viridian Therapeutics' financial condition and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any new material events or risks.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- Miragen Therapeutics, Inc. (company) — Former Company Name
- Signal Genetics, Inc. (company) — Former Company Name
- November 12, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Viridian Therapeutics, Inc.?
The primary purpose is to report on the company's results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements.
When was this 8-K filing submitted?
The filing was submitted on November 12, 2024.
What were Viridian Therapeutics, Inc.'s previous names?
Viridian Therapeutics, Inc. was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
In which state is Viridian Therapeutics, Inc. incorporated?
Viridian Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Viridian Therapeutics, Inc.?
The business address is 221 Crescent Street, Suite 103A, Waltham, MA 02453.
Filing Stats: 638 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-11-12 07:15:33
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
Filing Documents
- d911553d8k.htm (8-K) — 28KB
- d911553dex991.htm (EX-99.1) — 71KB
- d911553dex992.htm (EX-99.2) — 52KB
- g911553ex99_2s10g1.jpg (GRAPHIC) — 100KB
- g911553ex99_2s11g1.jpg (GRAPHIC) — 118KB
- g911553ex99_2s12g1.jpg (GRAPHIC) — 130KB
- g911553ex99_2s13g1.jpg (GRAPHIC) — 32KB
- g911553ex99_2s14g1.jpg (GRAPHIC) — 106KB
- g911553ex99_2s15g1.jpg (GRAPHIC) — 81KB
- g911553ex99_2s16g1.jpg (GRAPHIC) — 85KB
- g911553ex99_2s17g1.jpg (GRAPHIC) — 114KB
- g911553ex99_2s18g1.jpg (GRAPHIC) — 105KB
- g911553ex99_2s19g1.jpg (GRAPHIC) — 87KB
- g911553ex99_2s1g1.jpg (GRAPHIC) — 51KB
- g911553ex99_2s20g1.jpg (GRAPHIC) — 99KB
- g911553ex99_2s21g1.jpg (GRAPHIC) — 93KB
- g911553ex99_2s22g1.jpg (GRAPHIC) — 86KB
- g911553ex99_2s23g1.jpg (GRAPHIC) — 91KB
- g911553ex99_2s24g1.jpg (GRAPHIC) — 36KB
- g911553ex99_2s25g1.jpg (GRAPHIC) — 81KB
- g911553ex99_2s26g1.jpg (GRAPHIC) — 108KB
- g911553ex99_2s27g1.jpg (GRAPHIC) — 104KB
- g911553ex99_2s28g1.jpg (GRAPHIC) — 100KB
- g911553ex99_2s29g1.jpg (GRAPHIC) — 109KB
- g911553ex99_2s2g1.jpg (GRAPHIC) — 268KB
- g911553ex99_2s30g1.jpg (GRAPHIC) — 98KB
- g911553ex99_2s31g1.jpg (GRAPHIC) — 84KB
- g911553ex99_2s32g1.jpg (GRAPHIC) — 30KB
- g911553ex99_2s33g1.jpg (GRAPHIC) — 100KB
- g911553ex99_2s34g1.jpg (GRAPHIC) — 100KB
- g911553ex99_2s35g1.jpg (GRAPHIC) — 74KB
- g911553ex99_2s36g1.jpg (GRAPHIC) — 132KB
- g911553ex99_2s37g1.jpg (GRAPHIC) — 105KB
- g911553ex99_2s38g1.jpg (GRAPHIC) — 81KB
- g911553ex99_2s39g1.jpg (GRAPHIC) — 101KB
- g911553ex99_2s3g1.jpg (GRAPHIC) — 78KB
- g911553ex99_2s40g1.jpg (GRAPHIC) — 83KB
- g911553ex99_2s41g1.jpg (GRAPHIC) — 107KB
- g911553ex99_2s42g1.jpg (GRAPHIC) — 98KB
- g911553ex99_2s4g1.jpg (GRAPHIC) — 64KB
- g911553ex99_2s5g1.jpg (GRAPHIC) — 107KB
- g911553ex99_2s6g1.jpg (GRAPHIC) — 36KB
- g911553ex99_2s7g1.jpg (GRAPHIC) — 124KB
- g911553ex99_2s8g1.jpg (GRAPHIC) — 95KB
- g911553ex99_2s9g1.jpg (GRAPHIC) — 89KB
- g911553g1112092322470.jpg (GRAPHIC) — 2KB
- g911553g87x65.jpg (GRAPHIC) — 7KB
- 0001193125-24-255130.txt ( ) — 5790KB
- vrdn-20241112.xsd (EX-101.SCH) — 3KB
- vrdn-20241112_lab.xml (EX-101.LAB) — 18KB
- vrdn-20241112_pre.xml (EX-101.PRE) — 11KB
- d911553d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits . Exhibit Number Exhibit Description 99.1 Press release, dated November 12, 2024 99.2 Corporate Presentation, dated November 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: November 12, 2024 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director